{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:24:50Z","timestamp":1786980290967,"version":"build-2736575974"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2023,10,18]],"date-time":"2023-10-18T00:00:00Z","timestamp":1697587200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,10,18]],"date-time":"2023-10-18T00:00:00Z","timestamp":1697587200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Shantou Medical and Health Science and Technology Planning Project","award":["220428166491813"],"award-info":[{"award-number":["220428166491813"]}]},{"name":"Shantou Medical and Health Science and Technology Planning Project","award":["210408216492660"],"award-info":[{"award-number":["210408216492660"]}]},{"name":"Shantou University Medical College Clinical Research Enhancement Initiative","award":["N0201424 (to CC and JC)"],"award-info":[{"award-number":["N0201424 (to CC and JC)"]}]},{"name":"Science and Technology Special Fund of Guangdong Province of China","award":["2019-132 (to CC)"],"award-info":[{"award-number":["2019-132 (to CC)"]}]},{"name":"Strategic and Special Fund for Science and Technology Innovation of Guangdong Province of China","award":["180918114960704 (to CC)"],"award-info":[{"award-number":["180918114960704 (to CC)"]}]},{"DOI":"10.13039\/100014718","name":"Innovative Research Group Project of the National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82173079 (to CC)"],"award-info":[{"award-number":["82173079 (to CC)"]}],"id":[{"id":"10.13039\/100014718","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1007\/s00520-023-08111-9","type":"journal-article","created":{"date-parts":[[2023,10,18]],"date-time":"2023-10-18T00:01:40Z","timestamp":1697587300000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy of fosaprepitant combined with tropisetron plus dexamethasone in preventing nausea and emesis during fractionated radiotherapy with weekly cisplatin chemotherapy: interim analysis of a randomized, prospective, clinical trial using competing risk analysis"],"prefix":"10.1007","volume":"31","author":[{"given":"Song","family":"Xie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruihong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yizhou","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingxin","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanxuan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoluan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruoheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yudong","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renxian","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengbing","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuangzhen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,18]]},"reference":[{"key":"8111_CR1","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1056\/NEJMra0706547","volume":"358","author":"PJ Hesketh","year":"2008","unstructured":"Hesketh PJ (2008) Chemotherapy-induced nausea and vomiting. N Engl J Med 358:2482\u20132494. https:\/\/doi.org\/10.1056\/NEJMra0706547","journal-title":"N Engl J Med"},{"key":"8111_CR2","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1007\/s00520-006-0173-z","volume":"15","author":"L Cohen","year":"2007","unstructured":"Cohen L, de Moor CA, Eisenberg P et al (2007) Chemotherapy-induced nausea and vomiting: incidence and impact on patient quality of life at community oncology settings. Support Care Cancer Off J Multinatl Assoc Support Care Cancer 15:497\u2013503. https:\/\/doi.org\/10.1007\/s00520-006-0173-z","journal-title":"Support Care Cancer Off J Multinatl Assoc Support Care Cancer"},{"key":"8111_CR3","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae). Antiemesis. Version 2.2022. 2022. Available from https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/antiemesis.pdf. Accessed October 10, 2022"},{"key":"8111_CR4","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s00520-016-3407-8","volume":"25","author":"CH Ruhlmann","year":"2017","unstructured":"Ruhlmann CH, Jahn F, Jordan K et al (2017) 2016 updated MASCC\/ESMO consensus recommendations: prevention of radiotherapy-induced nausea and vomiting. Support Care Cancer 25:309\u2013316. https:\/\/doi.org\/10.1007\/s00520-016-3407-8","journal-title":"Support Care Cancer"},{"key":"8111_CR5","unstructured":"Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update. Bottom Line 24"},{"key":"8111_CR6","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae). Cervical Cancer. Version 1.2022. 2022. Available from https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/cervical.pdf. Accessed October 10, 2022"},{"key":"8111_CR7","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae). Head and Neck Cancers. Version 2.2022. 2022. Available from https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/head-and-neck.pdf. Accessed October 10, 2022"},{"key":"8111_CR8","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1200\/JCO.1997.15.1.103","volume":"15","author":"PJ Hesketh","year":"1997","unstructured":"Hesketh PJ, Kris MG, Grunberg SM et al (1997) Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol 15:103\u2013109. https:\/\/doi.org\/10.1200\/JCO.1997.15.1.103","journal-title":"J Clin Oncol"},{"key":"8111_CR9","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s00520-010-1003-x","volume":"19","author":"SM Grunberg","year":"2011","unstructured":"Grunberg SM, Warr D, Gralla RJ et al (2011) Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity\u2014state of the art. Support Care Cancer 19:43\u201347. https:\/\/doi.org\/10.1007\/s00520-010-1003-x","journal-title":"Support Care Cancer"},{"key":"8111_CR10","doi-asserted-by":"publisher","unstructured":"(1999) Radiation-induced emesis: a prospective observational multicenter Italian trial. The Italian Group for Antiemetic Research in Radiotherapy. Int J Radiat Oncol Biol Phys 44:619\u2013625. https:\/\/doi.org\/10.1016\/s0360-3016(99)00055-3","DOI":"10.1016\/s0360-3016(99)00055-3"},{"key":"8111_CR11","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.radonc.2009.11.001","volume":"94","author":"E Maranzano","year":"2010","unstructured":"Maranzano E, De Angelis V, Pergolizzi S et al (2010) A prospective observational trial on emesis in radiotherapy: analysis of 1020 patients recruited in 45 Italian radiation oncology centers. Radiother Oncol J Eur Soc Ther Radiol Oncol 94:36\u201341. https:\/\/doi.org\/10.1016\/j.radonc.2009.11.001","journal-title":"Radiother Oncol J Eur Soc Ther Radiol Oncol"},{"key":"8111_CR12","doi-asserted-by":"publisher","first-page":"3425","DOI":"10.1007\/s00520-013-1926-0","volume":"21","author":"CH Ruhlmann","year":"2013","unstructured":"Ruhlmann CH, Belli C, Dahl T, Herrstedt J (2013) Palonosetron and prednisolone for the prevention of nausea and emesis during fractionated radiotherapy and 5 cycles of concomitant weekly cisplatin\u2014a phase II study. Support Care Cancer 21:3425\u20133431. https:\/\/doi.org\/10.1007\/s00520-013-1926-0","journal-title":"Support Care Cancer"},{"key":"8111_CR13","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/S1470-2045(15)00615-4","volume":"17","author":"CH Ruhlmann","year":"2016","unstructured":"Ruhlmann CH, Christensen TB, Dohn LH et al (2016) Efficacy and safety of fosaprepitant for the prevention of nausea and emesis during 5 weeks of chemoradiotherapy for cervical cancer (the GAND-emesis study): a multinational, randomized, placebo-controlled, double-blind, phase 3 trial. Lancet Oncol 17:509\u2013518. https:\/\/doi.org\/10.1016\/S1470-2045(15)00615-4","journal-title":"Lancet Oncol"},{"key":"8111_CR14","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1097\/COC.0000000000000117","volume":"40","author":"A Mitsuhashi","year":"2017","unstructured":"Mitsuhashi A, Usui H, Nishikimi K et al (2017) The efficacy of palonosetron plus dexamethasone in preventing chemoradiotherapy-induced nausea and emesis in patients receiving daily low-dose cisplatin-based concurrent chemoradiotherapy for uterine cervical cancer: a phase II study. Am J Clin Oncol 40:118\u2013121. https:\/\/doi.org\/10.1097\/COC.0000000000000117","journal-title":"Am J Clin Oncol"},{"key":"8111_CR15","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","volume":"94","author":"JP Fine","year":"1999","unstructured":"Fine JP, Gray RJ (1999) A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94:496\u2013509. https:\/\/doi.org\/10.1080\/01621459.1999.10474144","journal-title":"J Am Stat Assoc"},{"key":"8111_CR16","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/sj.bmt.1705727","volume":"40","author":"L Scrucca","year":"2007","unstructured":"Scrucca L, Santucci A, Aversa F (2007) Competing risk analysis using R: an easy guide for clinicians. Bone Marrow Transplant 40:381\u2013387. https:\/\/doi.org\/10.1038\/sj.bmt.1705727","journal-title":"Bone Marrow Transplant"},{"key":"8111_CR17","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1214\/aos\/1176350951","volume":"16","author":"RJ Gray","year":"1988","unstructured":"Gray RJ (1988) A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 16:1141\u20131154","journal-title":"Ann Stat"},{"key":"8111_CR18","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1002\/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.0.CO;2-O","volume":"18","author":"TA Gooley","year":"1999","unstructured":"Gooley TA, Leisenring W, Crowley J, Storer BE (1999) Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 18:695\u2013706. https:\/\/doi.org\/10.1002\/(SICI)1097-0258(19990330)18:6%3c695::AID-SIM60%3e3.0.CO;2-O","journal-title":"Stat Med"},{"key":"8111_CR19","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1111\/j.1532-5415.2010.02767.x","volume":"58","author":"SD Berry","year":"2010","unstructured":"Berry SD, Ngo L, Samelson EJ, Kiel DP (2010) Competing risk of death: an important consideration in studies of older adults: competing risk of death in studies of older adults. J Am Geriatr Soc 58:783\u2013787. https:\/\/doi.org\/10.1111\/j.1532-5415.2010.02767.x","journal-title":"J Am Geriatr Soc"},{"key":"8111_CR20","doi-asserted-by":"publisher","first-page":"2389","DOI":"10.1002\/sim.2712","volume":"26","author":"H Putter","year":"2007","unstructured":"Putter H, Fiocco M, Geskus RB (2007) Tutorial in biostatistics: competing risks and multi-state models. Stat Med 26:2389\u20132430. https:\/\/doi.org\/10.1002\/sim.2712","journal-title":"Stat Med"},{"key":"8111_CR21","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1093\/jnci\/dji084","volume":"97","author":"ATC Chan","year":"2005","unstructured":"Chan ATC, Leung SF, Ngan RKC et al (2005) Overall survival after concurrent cisplatin-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma. J Natl Cancer Inst 97:536\u2013539. https:\/\/doi.org\/10.1093\/jnci\/dji084","journal-title":"J Natl Cancer Inst"},{"key":"8111_CR22","doi-asserted-by":"publisher","first-page":"e577","DOI":"10.1016\/j.ijrobp.2011.05.002","volume":"81","author":"S-Y Ryu","year":"2011","unstructured":"Ryu S-Y, Lee W-M, Kim K et al (2011) Randomized clinical trial of weekly vs. triweekly cisplatin-based chemotherapy concurrent with radiotherapy in the treatment of locally advanced cervical cancer. Int J Radiat Oncol Biol Phys 81:e577-581. https:\/\/doi.org\/10.1016\/j.ijrobp.2011.05.002","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"8111_CR23","doi-asserted-by":"publisher","first-page":"3117","DOI":"10.21873\/anticanres.15800","volume":"42","author":"A Uno","year":"2022","unstructured":"Uno A, Yamamoto S, Iihara H et al (2022) Control and risk factors of nausea and vomiting in patients with cervical cancer receiving radiotherapy. Anticancer Res 42:3117\u20133123. https:\/\/doi.org\/10.21873\/anticanres.15800","journal-title":"Anticancer Res"},{"key":"8111_CR24","doi-asserted-by":"publisher","first-page":"2783","DOI":"10.1007\/s00520-013-1855-y","volume":"21","author":"C Lanzarotti","year":"2013","unstructured":"Lanzarotti C, Rossi G (2013) Effect of netupitant, a highly selective NK1 receptor antagonist, on the pharmacokinetics of midazolam, erythromycin, and dexamethasone. Support Care Cancer 21:2783\u20132791. https:\/\/doi.org\/10.1007\/s00520-013-1855-y","journal-title":"Support Care Cancer"},{"key":"8111_CR25","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1634\/theoncologist.12-6-738","volume":"12","author":"JR Kouvaris","year":"2007","unstructured":"Kouvaris JR, Kouloulias VE, Vlahos LJ (2007) Amifostine: the first selective-target and broad-spectrum radioprotector. Oncologist 12:738\u2013747. https:\/\/doi.org\/10.1634\/theoncologist.12-6-738","journal-title":"Oncologist"},{"key":"8111_CR26","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1177\/0022034518767408","volume":"97","author":"JJ Varghese","year":"2018","unstructured":"Varghese JJ, Schmale IL, Mickelsen D et al (2018) Localized delivery of amifostine enhances salivary gland radioprotection. J Dent Res 97:1252\u20131259. https:\/\/doi.org\/10.1177\/0022034518767408","journal-title":"J Dent Res"},{"key":"8111_CR27","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.radonc.2003.10.005","volume":"70","author":"D Rades","year":"2004","unstructured":"Rades D, Fehlauer F, Bajrovic A et al (2004) Serious adverse effects of amifostine during radiotherapy in head and neck cancer patients. Radiother Oncol 70:261\u2013264. https:\/\/doi.org\/10.1016\/j.radonc.2003.10.005","journal-title":"Radiother Oncol"},{"key":"8111_CR28","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.ijrobp.2006.08.044","volume":"67","author":"PR Ann\u00e9","year":"2007","unstructured":"Ann\u00e9 PR, Machtay M, Rosenthal DI et al (2007) A phase II trial of subcutaneous amifostine and radiation therapy in patients with head-and-neck cancer. Int J Radiat Oncol 67:445\u2013452. https:\/\/doi.org\/10.1016\/j.ijrobp.2006.08.044","journal-title":"Int J Radiat Oncol"},{"key":"8111_CR29","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1093\/annonc\/mdx100","volume":"28","author":"G Dranitsaris","year":"2017","unstructured":"Dranitsaris G, Molassiotis A, Clemons M et al (2017) The development of a prediction tool to identify cancer patients at high risk for chemotherapy-induced nausea and vomiting. Ann Oncol 28:1260\u20131267. https:\/\/doi.org\/10.1093\/annonc\/mdx100","journal-title":"Ann Oncol"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-023-08111-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-023-08111-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-023-08111-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,14]],"date-time":"2023-12-14T05:08:22Z","timestamp":1702530502000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-023-08111-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,18]]},"references-count":29,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["8111"],"URL":"https:\/\/doi.org\/10.1007\/s00520-023-08111-9","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,18]]},"assertion":[{"value":"26 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of Cancer Hospital of Shantou University Medical College.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All participants provided written informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"This manuscript does not contain any individual person\u2019s data in any form.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"640"}}